Analyst firms · Raymond James · PRQR
Raymond James PRQR price target and rating history
ProQR Therapeutics N.V. (PRQR) · Health Care
Raymond James rates ProQR Therapeutics N.V. (PRQR) Strong Buy with a $14 price target, as of its latest action on Oct 29, 2024. It has published 4 rating actions on PRQR since February 2022, including 1 upgrade and 2 downgrades.
- Current rating
- Strong Buy
- Price target
- $14
- Median target, all firms
- Too few
- Actions on PRQR
- 4
Raymond James price target on PRQR
Every Raymond James rating on PRQR
- Oct 29, 2024
- Feb 14, 2022
- Feb 11, 2022
- Feb 1, 2022
How other firms rate PRQR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BofA Securities | Buy | $8 | Aug 20, 2026 |
| Oppenheimer | Outperform | $9 | Mar 12, 2026 |
Questions about Raymond James and PRQR
- What is Raymond James's price target for PRQR?
- Raymond James's latest stated price target for ProQR Therapeutics N.V. (PRQR) is $14, from its action on Oct 29, 2024.
- What is Raymond James's rating on PRQR?
- Raymond James rates PRQR Strong Buy, a bullish rating, as of Oct 29, 2024.
- When did Raymond James last change its view on PRQR?
- On Oct 29, 2024, Raymond James upgrades to Strong Buy from Outperform, price target $6 to $14.
More PRQR rating histories
All Raymond James ratingsPRQR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.